Adaptimmune NY-ESO-1/LAGE-1a TCR-engineered T cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Adaptimmune NY-ESO-1/LAGE-1a TCR-engineered T cells, covering 2024-05-10 to 2024-05-10. Get the full timeline:
Most recent: Clinical Trial Update: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors [Phase 1]